Eli Lilly and Co LLY
Price chart
Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.
Community Sentiment on LLY
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Strategy Backtest
Pick a strategy above and run the backtest to see its simulated performance on LLY.
Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.
LLY at a glance
LLY is priced at $1,354.00 right now, down 0.79% on the session. That puts its market value at $1.27T, 13th largest among the 3753 stocks we cover.
The stock's 52-week band runs $847.83 to $1,453.00, and the latest print sits 6.8% under the top end of it. Holders are ahead 47.4% over twelve months, and up 10.1% across the last three months.
On the chart it holds above both the 50-day ($1,214.25) and 200-day ($1,097.80) moving averages; RSI is 61, and the last 30 sessions moved at roughly 34% annualized volatility.
Revenue for the quarter ended Sep 2026 was $24.40B, up 38.6% from a year earlier, with $6.45B of net profit (a 31.9% margin).
Buyers are paying 43.9 times trailing earnings, 35% below its five-year average of 67.6.
24 analysts follow the stock and the average call is "buy". The mean target, $1,511.30, sits 11.6% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
BeStock Grade
Composite of 4 factors below, ranked against the 3741 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Higher trailing yield than most of BeStock’s coverage scores higher.
Trading closer to its 52-week high than most peers scores higher.
24 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
BeStock Momentum
LLY is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2020-12-28, the strategy has returned 437.6% (203.9% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.
Price forecast
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $1,511.30, 11.6% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $980.00, so shares trade 38.2% above that estimate. On earnings multiple, it sits in the 27th percentile of its own five-year valuation range (cheaper than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Eli Lilly and Co: the business
Eli Lilly develops diabetes, obesity, cancer and immunology drugs, including Mounjaro, Zepbound and Verzenio.
What tends to move it. Sales of its GLP-1 obesity and diabetes drugs, supply capacity and competition from Novo Nordisk drive the stock.
Where the case gets weaker. GLP-1 demand has to keep growing, and Lilly has to keep its share of it, for the valuation to hold up. New competition, insurance coverage fights, or supply catching up with demand would each chip away at that, and pipeline drugs outside the obesity and diabetes franchise matter less to the stock right now than they probably should.
Written by hand by the BeStock desk and revised when a business changes. how we work. Spot something out of date? Tell us.
Performance
Price return over each window, from adjusted daily and weekly closes
Technical signals
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | +4.0% | Bullish |
| Price vs 50-day average | +11.5% | Bullish |
| Price vs 200-day average | +23.3% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 61.1 | Bullish |
| MACD (12,26,9) | 52.93 | Bullish |
| Bollinger band position | 67% | Bullish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Key statistics
Quote as of Nov 9, 2026 1:30 am ET. Prices can lag the live tape. This is background information, not a recommendation.
How LLY ranks on BeStock
Ranks are among the 3,741 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
LLY stock: common questions
How is Eli Lilly and Co stock doing today?
$1,354.00 is the latest print for LLY, a move of -0.79% against yesterday's close of $1,364.73. Today's low and high so far: $1,333.22 and $1,377.28.
What is LLY worth in total?
Equity value comes to $1.27T at the current price. By that measure it is number 13 of the 3753 names in our coverage.
How is Eli Lilly and Co valued against its profits?
Buyers pay 43.9 times the last twelve months of profit (EPS $22.95). Averaged over five years the multiple has been 67.6, and today's level ranks in the 27th percentile of its own history.
Is LLY near its 52-week high or low?
The year's floor is $847.83 and the ceiling $1,453.00. Shares are 6.8% away from that ceiling.
Does Eli Lilly and Co pay a dividend?
It does. Payouts over the past twelve months work out to a 0.49% yield; the latest ex-dividend date was August 14, 2026.
Is LLY rated a buy by Wall Street?
Of 24 analysts, 92% say buy, 4% hold and 4% sell. Price targets average $1,511.30, with the most cautious at $940.00 and the most optimistic at $1,650.00.
What kind of company is Eli Lilly and Co?
Eli Lilly develops diabetes, obesity, cancer and immunology drugs, including Mounjaro, Zepbound and Verzenio.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on LLY.
Sign in to join the discussion.